Celastrol and Resveratrol Modulate <em>SIRT</em> Genes Expression and Exert Anticancer Activity in Colon Cancer Cells and Cancer Stem-like Cells

Metastatic colorectal cancer (CRC) remains a hard-to-cure neoplasm worldwide. Its curability declines with successive lines of treatment due to the development of various cancer resistance mechanisms and the presence of colorectal cancer stem cells (CSCs). Celastrol and resveratrol are very promisin...

Full description

Bibliographic Details
Main Authors: Helena Moreira, Anna Szyjka, Justyna Grzesik, Katarzyna Pelc, Magdalena Żuk, Anna Kulma, Fathi Emhemmed, Christian D. Muller, Kazimierz Gąsiorowski, Ewa Barg
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/14/6/1372
Description
Summary:Metastatic colorectal cancer (CRC) remains a hard-to-cure neoplasm worldwide. Its curability declines with successive lines of treatment due to the development of various cancer resistance mechanisms and the presence of colorectal cancer stem cells (CSCs). Celastrol and resveratrol are very promising phytochemicals for colon cancer therapy, owing to their pleiotropic activity that enables them to interact with various biological targets. In the present study, the anticancer activities of both compounds were investigated in metastatic colon cancer cells (LoVo cells) and cancer stem-like cells (LoVo/DX). We showed that celastrol is a very potent anti-tumor compound against metastatic colon cancer, capable of attenuating CSC-like cells at the molecular and cellular levels. In contrast, resveratrol has a much greater effect on colon cancer cells that are expressing standard sensitivity to anticancer drugs, than on CSC-like cells. In addition, both polyphenols have different influences on the expression of <i>SIRT</i> genes, which seems to be at least partly related to their anti-tumor activity.
ISSN:2072-6694